Edmond DE Rothschild Holding S.A. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Edmond DE Rothschild Holding S.A. has reduced its stake in BioNTech SE by 15.4%, now holding 82,310 shares valued at approximately $7.5 million.
• Despite the reduction, several other institutional investors have increased their holdings in BioNTech, contributing to a total of 15.52% of stock owned by such investors.
• Analysts have mixed sentiments on BioNTech's stock, with an average target price of $135.80 and thirteen analysts rating it as a Buy.

Edmond DE Rothschild Holding S.A. decreased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 15.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,310 shares of the company's stock after selling 15,000 shares during the quarter. Edmond DE Rothschild Holding S.A.'s holdings in BioNTech were worth $7,495,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in BNTX. Banque Cantonale Vaudoise acquired a new position in BioNTech during the first quarter worth approximately $36,000. Banque Transatlantique SA acquired a new position in BioNTech during the first quarter worth approximately $80,000. Costello Asset Management INC acquired a new position in BioNTech during the first quarter worth approximately $91,000. Goodman Advisory Group LLC acquired a new position in BioNTech during the first quarter worth approximately $105,000. Finally, Whittier Trust Co. increased its position in BioNTech by 3,846.2% during the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after buying an additional 2,000 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Price Performance

Shares of BioNTech stock traded down $1.18 during trading on Wednesday, reaching $100.91. The company's stock had a trading volume of 488,647 shares, compared to its average volume of 935,650. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12-month low of $81.20 and a 12-month high of $131.49. The company has a market capitalization of $24.26 billion, a P/E ratio of -63.16 and a beta of 1.39. The business has a 50 day moving average price of $109.30 and a 200-day moving average price of $104.19.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. During the same quarter last year, the firm earned ($3.36) earnings per share. The firm's quarterly revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BNTX shares. HC Wainwright reaffirmed a "buy" rating and set a $136.00 price target on shares of BioNTech in a research report on Monday. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. The Goldman Sachs Group started coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. JPMorgan Chase & Co. cut their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Finally, Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and an average target price of $135.80.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.